Current guidelines on treating cancer fatigue suggest that stimulants like methylphenidate be used sparingly if at all. But a recent meta-analysis supports a bigger role for the medications, possibly as a bridge to nondrug therapies.

The analysis, published in the Journal of the National Comprehensive Cancer Network, found that across nine randomized clinical trials, methylphenidate had a clinically meaningful impact on fatigue among patients who had advanced cancer or were actively undergoing cancer treatment.

The benefit emerged after at least 5 weeks of methylphenidate treatment, suggesting that may be the necessary time window to see meaningful results.

The findings do not imply that psychostimulants should replace recommended first-line therapies for fatigue, such as exercise and cognitive behavioral therapy (CBT), said lead researcher Bruno Almeida Costa, MD, of MD Anderson Cancer Center, in Houston.

However, he told Medscape Medical News, the medications might serve as a useful “bridge therapy,” helping patients attain the energy and motivation they need to avail themselves of exercise programs or psychotherapy.

A Widespread Problem

Fatigue is among the most prevalent and debilitating symptoms that people with cancer face. It’s estimated that over 80% of patients experience fatigue during chemotherapy or radiotherapy, while many also report fatigue before and after treatment.

Current guidelines from both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) list nonpharmacologic approaches — including exercise, CBT, yoga, and mindfulness programs — as first-line treatment.

The groups’ guidelines diverge somewhat on methylphenidate and other stimulants, though neither gives a ringing endorsement: ASCO advises against routine use of the medications, while the NCCN considers the drugs an option, in “selected circumstances, with caution.”

Chandana Banerjee, MD, of City of Hope in Los Angeles, helped draft the latest NCCN guideline. She said that nondrug interventions remain the therapy of choice because there’s good evidence they generally outperform medications.

The evidence supporting stimulants has been mixed at best, Banerjee told Medscape Medical News, so methylphenidate should be reserved for patients with severe or refractory fatigue.

In fact, no drug has been approved specifically for cancer fatigue, Costa and his colleagues pointed out — reflecting both the complexity of the condition and mixed results from clinical trials.

In the case of methylphenidate, most trials have been small, involving fewer than 100 patients, and they’ve varied in many respects, including the duration of methylphenidate treatment.

To help clarify the state of the evidence, Costa’s team performed a systematic review and meta-analysis of nine placebo-controlled randomized trials involving 832 patients with cancer-related fatigue.

The trials used Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scores, patient self-rated scales, and other validated scales to measure the efficacy of methylphenidate against placebo over a period of 8 weeks or more.

Overall, Costa’s team found, methylphenidate produced modest but statistically significant improvements in fatigue vs placebo. And FACIT-F scores rose with longer treatment — surpassing the three-point threshold for clinical meaningfulness after 5 weeks of therapy.

Importantly, the analysis found no increased risk for side effects such as dizziness, palpitations, anxiety, or gastrointestinal symptoms among patients taking methylphenidate.

Building a Bridge

Costa stressed that the findings are not the final word. For one, the meta-analysis could not fully account for the placebo effect, which was strong across studies.

At the same time, Costa said it’s plausible that methylphenidate — which acts on neurotransmitters linked to motivation, concentration, and perceived energy levels — has real effects on cancer fatigue.

He and Banerjee agreed that for many patients with advanced cancers, taking up exercise or enrolling in CBT or mindfulness programs can be challenging.

Along with fatigue, Banerjee noted, many patients also struggle with pain, emotional distress, and practical barriers such as transportation and the demands of daily life.

Given the reassuring safety data on methylphenidate, Costa said, it might be worth trying the drug for at least 5 weeks with a goal of making first-line interventions more feasible. Once patients take up exercise or other programs, he added, they may be able to discontinue methylphenidate.

Based on the existing evidence, side effects are more likely with extended-release methylphenidate or high doses. Costa recommended patients be prescribed short-acting methylphenidate, starting at low doses (5-10 mg/d) and increasing to up to 30 mg daily, depending on their response and any adverse effects.

Tailoring to Patient Needs

Despite current guidelines and conflicting trial results, many physicians are already prescribing methylphenidate to patients with cancer fatigue, based on anecdotal evidence.

“That certainly is the case for me, and I think a lot of my colleagues would speak to that,” said Nicolas Chin-Yee, MD, of Princess Margaret Cancer Center in Toronto, Ontario, Canada.

Chin-Yee has studied various therapeutic approaches to cancer fatigue and co-wrote an editorial published in the Journal of Clinical Oncology on methylphenidate’s potential role.

He believes the debate is far from over but agreed that reframing methylphenidate as a bridge therapy to longer-term interventions could prove useful.

Chin-Yee also pointed to the potential of combination therapies. One trial, just reported at this year’s ASCO annual meeting, found that a combination of methylphenidate and exercise over 12 weeks beat placebo in easing fatigue among patients with advanced prostate cancer.

According to Chin-Yee, the ideal patient for such combination therapies would be those with advanced cancers who are still ambulatory and free of risk factors (cardiovascular or psychiatric) for adverse effects from psychostimulants.

And because methylphenidate works on mood and motivation in the brain, Chin-Yee said, fatigue characterized by cognitive and/or emotional elements may respond best to the drug.

Ultimately, all three experts agreed, larger and longer trials will be necessary to solidify the role of stimulants.

According to Costa, future trials should track patients for months, not weeks, and attempt to more accurately tease out the role of the placebo effect in methylphenidate’s benefits.

In the meantime, Banerjee said that while the recommended nondrug options can be challenging for patients, there are ways clinicians can help. She suggested encouraging “small, achievable” changes — such as brief daily walks, stretching, breathing exercises, and paying attention to sleep habits.

Incremental steps, Banerjee said, “may be more realistic and ultimately more effective than expecting patients to adopt major lifestyle changes.”

Costa, Banerjee, and Chin-Yee had no relevant financial disclosures.